Hiroshi Tsubamoto1, Takashi Sonoda2, Kayo Inoue3. 1. Department of Obstetrics and Gynecology, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan tsuba@hyo-med.ac.jp. 2. Department of Medical Oncology, Kohnan Hospital, Higashinada-ku, Kobe, Japan. 3. Department of Obstetrics and Gynecology, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan Department of Obstetrics and Gynecology, Meiwa General Hospital, Nishinomiya, Hyogo, Japan.
Abstract
BACKGROUND/AIM: Recurrent triple-negative breast cancer (TNBC) patients have poor prognoses and limited treatment options, especially after progression during prior chemotherapy. The present study aimed to determine the impact of itraconazole with chemotherapy in these patients. PATIENTS AND METHODS: Medical records of recurrent TNBC patients receiving itraconazole with chemotherapy between 2008 and 2012 were retrospectively reviewed. RESULTS: Thirteen patients who progressed during prior chemotherapy (12 with visceral organ metastases) were enrolled. All patients had received docetaxel, carboplatin, and gemcitabine with itraconazole. Additionally, 3 patients with pleural effusion and 2 with inflammatory breast cancer received bevacizumab. No febrile neutropenia, platelet transfusion, or chemotherapy-related death was observed during treatment with itraconazole. The response rate, median progression-free survival, and median overall survival were 62% (95% confidence interval (CI): 35-88%), 10.8 months (95%CI: 7.6-15.3 months), and 20.4 months (95%CI: 13.1-41.4 months), respectively. CONCLUSION: Chemotherapy with itraconazole is promising for heavily pre-treated TNBC patients. Copyright
BACKGROUND/AIM: Recurrent triple-negative breast cancer (TNBC) patients have poor prognoses and limited treatment options, especially after progression during prior chemotherapy. The present study aimed to determine the impact of itraconazole with chemotherapy in these patients. PATIENTS AND METHODS: Medical records of recurrent TNBC patients receiving itraconazole with chemotherapy between 2008 and 2012 were retrospectively reviewed. RESULTS: Thirteen patients who progressed during prior chemotherapy (12 with visceral organ metastases) were enrolled. All patients had received docetaxel, carboplatin, and gemcitabine with itraconazole. Additionally, 3 patients with pleural effusion and 2 with inflammatory breast cancer received bevacizumab. No febrile neutropenia, platelet transfusion, or chemotherapy-related death was observed during treatment with itraconazole. The response rate, median progression-free survival, and median overall survival were 62% (95% confidence interval (CI): 35-88%), 10.8 months (95%CI: 7.6-15.3 months), and 20.4 months (95%CI: 13.1-41.4 months), respectively. CONCLUSION: Chemotherapy with itraconazole is promising for heavily pre-treated TNBC patients. Copyright
Authors: Sarah A Head; Wei Shi; Liang Zhao; Kirill Gorshkov; Kalyan Pasunooti; Yue Chen; Zhiyou Deng; Ruo-jing Li; Joong Sup Shim; Wenzhi Tan; Thomas Hartung; Jin Zhang; Yingming Zhao; Marco Colombini; Jun O Liu Journal: Proc Natl Acad Sci U S A Date: 2015-12-10 Impact factor: 11.205
Authors: Asmaa Waheed Mohamed; Mohamed Elbassiouny; Dalia Abdelghany Elkhodary; May Ahmed Shawki; Amr Shafik Saad Journal: Med Oncol Date: 2021-02-09 Impact factor: 3.064
Authors: Wei Zhang; Ankur S Bhagwath; Zeeshan Ramzan; Taylor A Williams; Indhumathy Subramaniyan; Vindhya Edpuganti; Raja Reddy Kallem; Kerry B Dunbar; Peiguo Ding; Ke Gong; Samuel A Geurkink; Muhammad S Beg; James Kim; Qiuyang Zhang; Amyn A Habib; Sung-Hee Choi; Ritu Lapsiwala; Gayathri Bhagwath; Jonathan E Dowell; Shelby D Melton; Chunfa Jie; William C Putnam; Thai H Pham; David H Wang Journal: Mol Cancer Ther Date: 2021-08-10 Impact factor: 6.261